THE problem of wasting ascites occurring in patients with cirrhosis of the liver is unsolved — both the pathogenesis of the ascites and its reliable cure. Recent observations have indicated the ...

W. L. Gore & Associates has reported the enrollment of the first patient in the Gore Early TIPS for Ascites Study at the Indiana University Hospital in Indianapolis. The objective of the study, which ...

Splenomegaly resulting from portal hypertension can be caused by cirrhosis, hepatic venous outflow tract obstruction and extrahepatic portal vein obstruction. Both cirrhosis and hepatic venous outflow ...

Eight patients with alcoholic cirrhosis and ascites were studied. In 4 patients, urine was collected from 8 a.m. to 12 noon, 12 noon to 3 p.m., 3 p.m. to 6 p.m. and 6 p.m. to 8 a.m. for two successive ...

SANTA MONICA, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver ...

Challenges in developing drugs for pancreatic ductal adenocarcinoma (PDAC) include obtaining metastatic cancer tissue for research and validating biomarkers predicative for personalised therapeutic ...

Investigators assessed the long-term outcomes of patients with cirrhosis and ascites switched from treatment with propranolol to carvedilol. Patients with cirrhosis and ascites had improved renal ...

This 29-year-old man developed new-onset ascites while in hospital. The patient has HIV infection, first diagnosed in 1994. He has been poorly compliant with his highly active antiretroviral therapy ...

Osimertinib in previously EGFR-TKI treated non-small cell lung cancer (NSCLC) patients without T790M mutation: Real-world evidence. Exploratory analysis of factors associated with hyperprogression in ...

CHENGDU, China--(BUSINESS WIRE)--Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed ...

The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD). Fibroblast growth factor receptor 4 (FGFR4) expression as a ...